Preview

Meditsinskiy sovet = Medical Council

Advanced search

ORIGINAL OR GENERIC DRUG: THE PROBLEM OF CHOICE OF ANTIBIOTIC DRUGS IN RUSSIA

https://doi.org/10.21518/2079-701X-2016-15-72-77

Abstract

Obviously, the key role in the treatment of infectious diseases often belongs to adequate and timely antibacterial therapy (ABT) which determines favorable clinical outcome, minimizes the risk of selection and spread of drug resistant pathogens, ultimately resulting in a lower cost of treatment. It is also practically assured that opting for a generic drug could reduce financial costs due to the price difference between generic and original (innovative) antibacterial drugs.

About the Authors

A. I. SINOPALNIKOV
Russian Medical Academy of Postgraduate Education, MoH RF
Russian Federation
MD, Prof.


E. A. STYRT
Russian Medical Academy of Postgraduate Education, MoH RF
Russian Federation
PhD in medicine


References

1. Белоусов Ю.Б. Дженерики – мифы и реалии. Ремедиум, 2003, 7-8: 4-9.

2. Agudelo M, Morales M, Cardeno J et al. Differences in therapeutic efficacy of a generic product of meropenem compared with the innovator in murine and cavian models of human infection. 49th ICAAC., San Francisco, California, USA, 12-15 eрtember 2009. A1-020.

3. Torres JA, Tafur JD, Briceno DF, Viollegas MV. Generic antibiotics are a risk factor for mortality in Acinetobacter baumannii infections in Colombian intensive care units.49th ICAAC., San Francisco, California, USA, 12-15 Seрtember 2009. K-312.

4. Nightingale CH. A survey of the Quality of Generic Clarithromycin Products From 18 Countries Disclosures. Clin Drug Invest, 2005, 25(2): 135-152.

5. Lambert PA, Conway BR. Pharmaceutical quality of ceftriaxone generic drug products compared with Rocephin. J Chemother, 2003 Aug, 15: 357-68.

6. Wetterich U, Mutschler E. Quality of cefotaxime sodium preparations. Arzneimittelforschung, 1995, 45: 74-80.

7. Никулин А.А., Цюман Ю.П., Мартинович А.А. и др. К вопросу о взаимозаменяемости внутривенных форм оригинальных и генерических препаратов: нужны ли сравнительные исследования? КМАХ, 2010, 12: 31-40.

8. www.accessdata.fda.gov/scripts.cder/ob/default.cfm

9. www.ema.europa.eu

10. www.roszdravnadzor.ru

11. Резолюция совета экспертов «Современные позиции макролидов в терапии инфекций дыхательных путей с учетом новых данных о резистентности респираторных патогенов в Российской Федерации» от 1 июня 2015 г., Москва. Consilium medicum (Болезни органов дыхания. Приложение), 2015, 01: 36-38.

12. Ball P, Baquero F, Cars O, et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. JAC, 2002, 49: 31-40.

13. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и соавт. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Клин Микробиол Антимикроб Химиотер, 2010, 3: 1-44.

14. Синопальников А.И., Фесенко О.В. Карманные рекомендации для врачей по ведению пациентов с внебольничной пневмонией. М.: ООО «Группа Ремедиум», 2016. 168 с. 15. www.rosminzdrav.ru


Review

For citations:


SINOPALNIKOV AI, STYRT EA. ORIGINAL OR GENERIC DRUG: THE PROBLEM OF CHOICE OF ANTIBIOTIC DRUGS IN RUSSIA. Meditsinskiy sovet = Medical Council. 2016;(15):72-77. (In Russ.) https://doi.org/10.21518/2079-701X-2016-15-72-77

Views: 725


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)